Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Falberg Kathryn E who is EVP and CFO at Jazz Pharmaceuticals sold 3,000 shares at $87.52 on Sept. 13, 2013. Following this transaction, the EVP and CFO owned 137,372 shares meaning that the stake was reduced by 2.14% with the 3,000 share transaction.

The shares most recently traded at $89.91, up $2.39, or 2.66% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 8,000
  • 12-Week # shares sold: 34,208
  • 24-Week # shares sold: 50,208

The average volume for Jazz Pharmaceuticals has been 791,300 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $5.1 billion and is part of the health care sector and drugs industry. Shares are up 64% year to date as of the close of trading on Friday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company has a P/E ratio of 18.6. Currently there are 12 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

Liquidity Service (LQDT) Strong On High Relative Volume Today

Insider Trading Alert - RAX, WEC And LQDT Traded By Insiders

Insider Trading Alert - RAX, WEC And LQDT Traded By Insiders

Liquidity Services (LQDT) Downgraded From Hold to Sell

Commit To Purchase Liquidity Services At $7.50, Earn 12.7% Annualized Using Options